West Oak Capital LLC Has $343,000 Stock Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

West Oak Capital LLC lessened its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 10.6% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 630 shares of the medical research company’s stock after selling 75 shares during the quarter. West Oak Capital LLC’s holdings in Thermo Fisher Scientific were worth $343,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in the company. Vanguard Group Inc. lifted its position in shares of Thermo Fisher Scientific by 0.6% during the 3rd quarter. Vanguard Group Inc. now owns 32,760,738 shares of the medical research company’s stock valued at $16,582,503,000 after acquiring an additional 180,618 shares during the period. State Street Corp increased its stake in Thermo Fisher Scientific by 0.3% in the second quarter. State Street Corp now owns 16,116,956 shares of the medical research company’s stock valued at $8,414,693,000 after purchasing an additional 55,458 shares in the last quarter. Morgan Stanley raised its holdings in shares of Thermo Fisher Scientific by 0.4% during the third quarter. Morgan Stanley now owns 12,418,429 shares of the medical research company’s stock valued at $6,285,838,000 after purchasing an additional 50,736 shares during the period. Moneta Group Investment Advisors LLC grew its stake in shares of Thermo Fisher Scientific by 104,536.8% in the 4th quarter. Moneta Group Investment Advisors LLC now owns 8,355,245 shares of the medical research company’s stock valued at $4,601,150,000 after buying an additional 8,347,260 shares during the period. Finally, Providence Capital Advisors LLC increased its holdings in shares of Thermo Fisher Scientific by 61,754.7% during the first quarter. Providence Capital Advisors LLC now owns 5,842,175 shares of the medical research company’s stock valued at $10,136,000 after acquiring an additional 5,832,730 shares in the last quarter. 89.23% of the stock is owned by institutional investors and hedge funds.

Thermo Fisher Scientific Stock Performance

Thermo Fisher Scientific stock traded up $1.41 during trading on Thursday, hitting $580.78. The stock had a trading volume of 223,218 shares, compared to its average volume of 1,604,234. The company has a quick ratio of 1.39, a current ratio of 1.75 and a debt-to-equity ratio of 0.67. The stock’s 50 day moving average is $564.32 and its two-hundred day moving average is $519.80. Thermo Fisher Scientific Inc. has a 1 year low of $415.60 and a 1 year high of $603.82. The stock has a market cap of $221.46 billion, a price-to-earnings ratio of 37.50, a price-to-earnings-growth ratio of 2.39 and a beta of 0.80.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Wednesday, January 31st. The medical research company reported $5.67 earnings per share for the quarter, topping the consensus estimate of $5.64 by $0.03. Thermo Fisher Scientific had a return on equity of 18.78% and a net margin of 13.99%. The company had revenue of $10.89 billion during the quarter, compared to the consensus estimate of $10.73 billion. During the same quarter in the prior year, the company earned $5.40 EPS. The firm’s quarterly revenue was down 4.9% compared to the same quarter last year. As a group, analysts predict that Thermo Fisher Scientific Inc. will post 21.52 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, April 15th. Investors of record on Friday, March 15th will be paid a $0.39 dividend. This represents a $1.56 dividend on an annualized basis and a yield of 0.27%. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. The ex-dividend date of this dividend is Thursday, March 14th. Thermo Fisher Scientific’s payout ratio is currently 10.10%.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on TMO shares. Robert W. Baird reaffirmed an “outperform” rating and issued a $670.00 price objective on shares of Thermo Fisher Scientific in a research note on Thursday, December 14th. Wolfe Research assumed coverage on Thermo Fisher Scientific in a report on Wednesday, December 13th. They set an “outperform” rating and a $575.00 price objective for the company. Royal Bank of Canada raised their target price on Thermo Fisher Scientific from $592.00 to $642.00 and gave the company an “outperform” rating in a report on Thursday, February 1st. TheStreet raised Thermo Fisher Scientific from a “c+” rating to a “b-” rating in a research report on Friday, December 22nd. Finally, Barclays lowered shares of Thermo Fisher Scientific from an “overweight” rating to an “equal weight” rating and upped their target price for the stock from $475.00 to $555.00 in a research note on Wednesday, January 24th. Five investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $599.00.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $597.98, for a total transaction of $5,979,800.00. Following the completion of the transaction, the chief executive officer now owns 123,816 shares of the company’s stock, valued at approximately $74,039,491.68. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 5,547 shares of the firm’s stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $550.62, for a total value of $3,054,289.14. Following the sale, the chief executive officer now owns 43,608 shares of the company’s stock, valued at approximately $24,011,436.96. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, March 12th. The stock was sold at an average price of $597.98, for a total transaction of $5,979,800.00. Following the completion of the transaction, the chief executive officer now owns 123,816 shares in the company, valued at $74,039,491.68. The disclosure for this sale can be found here. Insiders sold 50,277 shares of company stock valued at $28,513,384 over the last three months. Company insiders own 0.32% of the company’s stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.